• PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY

    Nov 1, 2019, 00:00

  • PNS235 ASSESSMENT OF DIGITAL HEALTH TECHNOLOGIES - COMPARISON OF EVIDENCE FRAMEWORKS OF NICE AND HAS

    Nov 1, 2019, 00:00

  • PCN422 BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB

    Nov 1, 2019, 00:00

  • PDB90 IS IT POSSIBLE TO AUTOMATE A SYSTEMATIC LITERATURE REVIEW?

    Nov 1, 2019, 00:00

  • PMU30 A SYSTEMATIC REVIEW OF PREVIOUSLY PUSBLISHED OR APPRAISED HEALTH ECONOMIC MODELS ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00

  • PCN509 REAL-WORLD EVIDENCE ON PATIENTS WITH RELAPSED/REFRACTORY FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA IN ITALY

    Nov 1, 2019, 00:00

  • PNS18 CAN REFLECTIVE MCDA CONTRIBUTE TO ACHIEVING EMA'S STRATEGIC OBJECTIVES FOR REGULATORY SCIENCE TO 2025? WHEN THE BOTTOM UP APPROACH CAN BE THE WAY TO GO: INSIGHTS FROM SPANISH EXPERIENCE

    Nov 1, 2019, 00:00

  • PNS257 PERCEPTIONS ON THE PHARMACISTS' ROLE IN HTA DECISION MAKING IN GREECE

    Nov 1, 2019, 00:00

  • Surgery - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN37 THE BENEFIT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS AGED 75 OR OLDER WITH STAGE III COLON CANCER

    Nov 1, 2019, 00:00

  • PCN254 CHARACTERISING INDIVIDUALS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING ROUTINE LINKED HEALTH DATASETS: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PSU33 REDUCTION IN DISCECTOMY TIME AND INSTRUMENT PASSES WITH THE CONCORDE® CLEAR MIS DISCECTOMY DEVICE FOR TRANSFORAMINAL LUMBAR INTERBODY FUSION DISCECTOMY

    Nov 1, 2019, 00:00

  • Comparative Effectiveness or Efficacy Studies

    Nov 1, 2019, 00:00

  • PCN357 PREDICTOR OF A POSITIVE RECOMMENDATION IN NICE ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PBI9 SYSTEMATIC LITERATURE REVIEW OF NMAS AND POPULATION ADJUSTED INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PSORIASIS

    Nov 1, 2019, 00:00

  • PIN56 EXCESS HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH PERTUSSIS INFECTION IN OLDER ADULTS

    Nov 1, 2019, 00:00

  • PRO17 A BUDGET IMPACT ANALYSIS OF ANTI-INHIBITOR COAGULANT COMPLEX USE IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS ACROSS KINGDOM OF SAUDI ARABIA.

    Nov 1, 2019, 00:00

  • PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D)

    Nov 1, 2019, 00:00

  • PCN264 ESTIMATING THE BURDEN OF SALIVARY GLAND CANCER IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00

  • PCV147 DATA QUALITY EVALUATION OF 5 MUNICIPAL AND PROVINCIAL CLAIMS DATABASES OF FUJIAN PROVINCE IN CHINA

    Nov 1, 2019, 00:00

  • PCV27 AN ECONOMIC ANALYSIS OF ENDOVASCULAR ARTERIOVENOUS FISTULAS IN DIALYSIS PATIENTS: A U.S. PAYER AND PROVIDER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDG98 A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM

    Nov 1, 2019, 00:00

  • PRO123 DEVELOPING AN EVIDENCE GENERATION PLAN FOR THE VALUE STORY OF AN ORPHAN DRUG

    Nov 1, 2019, 00:00

  • PBI88 ASSESSMENT OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS ELIGIBLE FOR BIOLOGIC AGENTS

    Nov 1, 2019, 00:00

  • PSY54 WEB SURVEY AND FOCUS GROUPS EXPLORING KNOWLEDGE, NEEDS AND EXPECTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS

    Nov 1, 2019, 00:00

  • Cancer - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA?

    Nov 1, 2019, 00:00

  • PCN75 EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER - A MULTIPLE COUNTRY ANALYSIS

    Nov 1, 2019, 00:00

  • PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS

    Nov 1, 2019, 00:00

  • PCN467 THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PSS20 CONFIRMATION OF THE MEASUREMENT PROPERTIES OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE 28 ITEM RASCH-BASED SCORING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00

  • PCV54 THE HEALTHCARE MANAGEMENT OF PATIENTS WITH THE CORONARY AND PERIPHERAL ARTERIAL DISEASES

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PND39 A COST-EFFECTIVENESS ANALYSIS OF PREGABALIN VS. DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN CHINA

    Nov 1, 2019, 00:00

  • PCN336 PARALLEL SCIENTIFIC ADVICE FROM NICE AND CADTH: WOULD ONE SUBMISSION FIT ALL?

    Nov 1, 2019, 00:00

  • PCN173 ACCOUNTING FOR TIME-DEPENDENT HEALTH STATE MEMBERSHIP IN BUDGET IMPACT ANALYSIS - CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PMU152 SWITCHING AMONG BIOLOGIC THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PND66 ASSESSING THE POTENTIALLY INAPPROPRIATE USE OF ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PATIENTS WITH PARKINSON DISEASE USING KOREA NATIONAL HEALTH INSURANCE CLAIMS DATA

    Nov 1, 2019, 00:00

  • PDG76 IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT?

    Nov 1, 2019, 00:00

  • PCN499 REAL WORLD TREATMENT AND SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: AN ANALYSIS USING JAPANESE CLAIMS DATA

    Nov 1, 2019, 00:00

  • PIN105 DESCRIPTION OF PATIENTS HOSPITALIZED WITH MENINGOCOCCAL INFECTIONS IN FRANCE: AN ANALYSIS OF THE NATIONAL HEALTHCARE CLAIM(SNIIR-AM) DATABASE

    Nov 1, 2019, 00:00

  • CP2 DO SOCIAL VALUES AND INSTITUTIONAL CONTEXT IMPACT THE USE OF ECONOMIC EVALUATION IN PRIORITY SETTING: EMPIRICAL EVIDENCE FROM OECD COUNTRIES

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PRS65 BEVACIZUMAB INDUCED PULMONARY EMBOLISM: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • Alternative Medicine Statistical Research

    Nov 1, 2019, 00:00

  • PCN356 ARE CANCER DRUGS ASSOCIATED WITH A COMPANION DIAGNOSTIC TEST TAKING LONGER TO BE REIMBURSED IN AUSTRALIA?

    Nov 1, 2019, 00:00

  • PMD8 ESTIMATING THE POTENTIAL CASES OF BLINDNESS AND COSTS AVOIDED AND IN REALLOCATING HEALTHCARE RESOURCE UTILIZATION FROM TREATING POSTERIOR CAPSULAR OPACIFICATION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00

  • PCN78 CHANGES IN HEALTH STATE COSTS IN HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PMU70 FACTORS INFLUENCING THE SELECTION OF PRODUCTS FOR THE ACCELERATED ACCESS COLLABORATIVE'S RAPID UPTAKE PATHWAY

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN47 REAL WORLD EVIDENCE OF DARATUMUMAB IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PCV154 A NOVEL PREDICTION FOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE

    Nov 1, 2019, 00:00

  • PMS12 PATIENTS PRESCRIBED WITH OPIOID TREATMENT IN PRIMARY CARE PRACTICES: A POPULATION-BASED STUDY IN ITALY

    Nov 1, 2019, 00:00

  • PRO85 THE APPRAISAL PROCESS OF HIGH COST DRUGS FOR RARE GENETIC DISEASES IN THE PUBLIC HEALTH SYSTEM IN BRAZIL

    Nov 1, 2019, 00:00

  • PCN480 RELEVANCE OF SELECTED PATIENT-REPORTED OUTCOME (PRO) MEASURES IN EPSTEIN-BARR VIRUS ASSOCIATED (EBV+) POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) PATIENTS

    Nov 1, 2019, 00:00

  • PNS401 THE FIRST PARALLEL EQ-5D-3L AND EQ-5D-5L COMPOSITE TIME TRADE-OFF VALUATION STUDY IN EUROPE

    Nov 1, 2019, 00:00

  • PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PNS213 NICE FAST TRACK APPRAISALS: A DESCRIPTIVE OVERVIEW

    Nov 1, 2019, 00:00

  • PDG36 ANALYSIS OF GABAPENTINOIDS ABUSE IN THE MIDDLE EAST AND NORTH AFRICA REGION UTILIZING THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENTS REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PCN32 COMPARATIVE EFFICACY OF PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS FIRST-LINE SYSTEMIC THERAPIES FOR ELDERLY PATIENTS WITH ADVANCED/METASTATIC RCC (MRCC): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PCV17 HEALTHCARE UTILIZATION PRIOR TO AN INITIAL DIAGNOSIS OF PAROXYSMAL SUPRVENTRICULAR TACHYCARDIA IN A LARGE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PRS60 IMPACT OF SLEEP DISTURBANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): WHAT DO WE KNOW SO FAR?

    Nov 1, 2019, 00:00

  • PCN407 SOMATOSTATIN ANALOGUES IN IMAGING OF BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PMU91 CURRENT TREND OF UTILITY VALUES IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISAL GUIDANCE

    Nov 1, 2019, 00:00

  • PMH2 BREXANOLONE INJECTION IN POSTPARTUM DEPRESSION: SUSTAINED REMISSION, SUSTAINED RESPONSE, AND NUMBER NEEDED TO TREAT

    Nov 1, 2019, 00:00

  • PCN35 SURVEILLANCE FOR PATIENTS WITH LI-FRAUMENI SYNDROME

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PND118 PATIENTS WITH CHRONIC PAIN DISORDERS: PREFERENCE OF EPRO SCREEN DISPLAY AND FEATURES

    Nov 1, 2019, 00:00

  • PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA

    Nov 1, 2019, 00:00

  • PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL

    Nov 1, 2019, 00:00

  • PMS74 TAPERING BIOLOGIC? AN INSIGHT AND PERSPECTIVE OF RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2019, 00:00

  • PSY15 COMPARISONS OF COSTS RELATED TO THE INITIATION OF TAPENTADOL OR OXYCODONE TREATMENT IN SPANISH PATIENTS SUFFERING FROM SEVERE NON-MALIGNANT PAIN

    Nov 1, 2019, 00:00

  • Medical Devices - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • Individual's Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PBI31 COST-EFFECTIVENESS COMPARISON OF RISANKIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SEVERE PSORIASIS

    Nov 1, 2019, 00:00

  • PIH28 A REAL WORLD ANALYSIS OF PREVALENCE OF SYMPTOMS AND HEALTHCARE UTILIZATION IN WOMEN WITH MENOPAUSE

    Nov 1, 2019, 00:00

  • PCN247 COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB VS TRASTUZUMAB IN NEOADJUVANT SETTING BASED ON THE NEOSPHERE TRIAL IN TURKEY

    Nov 1, 2019, 00:00

  • PMU137 A BIBLIOMETRIC ANALYSIS OF SOUTH AFRICAN HEALTH-RELATED QUALITY OF LIFE STUDIES RELEVANT TO ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PGI37 REDUCTION IN CO-THERAPY COSTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICAL DRUGS

    Nov 1, 2019, 00:00

  • PND102 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PMS20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-EXPERIENCED PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRS67 GENDER DIFFERENCES IN ASTHMA PERCEPTION AND IMPACT ON QUALITY OF LIFE: A POST-HOC ANALYSIS OF THE PROXIMA OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PNS178 PRIVATE HEALTH INSURANCE PERCEPTION OF THEIR ROLE AFTERWARD UNIVERSAL HEALTH INSURANCE IN EGYPT

    Nov 1, 2019, 00:00

  • PCN444 DYNAMIC SURVIVAL MODELS FOR INCORPORATING EXTERNAL EVIDENCE WHEN EXTRAPOLATING OVERALL SURVIVAL: A CASE STUDY.

    Nov 1, 2019, 00:00

  • PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB

    Nov 1, 2019, 00:00

  • PSU44 MANAGEMENT OF PERIPROCEDURAL THROMBOTIC AND BLEEDING EVENTS IN PERCUTANEOUS CORONARY INTERVENTIONS IN EUROPE: PILOT SURVEY OF TREATMENT STRATEGIES AND HOSPITAL RESOURCES USE

    Nov 1, 2019, 00:00

  • PMU39 CERVICAL CANCER PREVENTION THROUGH HUMAN PAPILLOMAVIRUS (HPV) VACCINATION: A CASE STUDY IN ETHIOPIA

    Nov 1, 2019, 00:00

  • Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention

    Nov 1, 2019, 00:00

  • PCN373 RECENT COST PER QALY TRENDS OF NON-HAEMATOLOGICAL CANCERS ASSESSMENT AT NICE

    Nov 1, 2019, 00:00

  • PDB106 DOES MOBILE HEALTH LIVE UP TO EXPECTATIONS? EXPLORING REAL-WORLD EXPERIENCES IN PATIENTS WITH DIABETES

    Nov 1, 2019, 00:00

  • PMH34 THE ECONOMIC BURDEN OF SCHIZOPHRENIA: A REAL-WORLD DATA ANALYSIS IN ITALY

    Nov 1, 2019, 00:00

  • PNS176 COMPARISON OF HOSPITAL BED NUMBERS IN EUROPEAN OECD COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS

    Nov 1, 2019, 00:00

  • PBI37 BIOSIMILAR INTERCHANGEABILITY, SUBSTITUTION AND SWITCHING: AN OVERVIEW OF 5 EUROPEAN MEMBER STATES AND THE UNITED STATES

    Nov 1, 2019, 00:00

  • PGI26 A BUDGET IMPACT ANALYSIS OF RIFAXIMIN FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN TERTIARY HOSPITAL,RIYADH, SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PCN410 USE OF EXTERNAL INFORMATION FROM HISTORICAL TRIAL DATA TO IMPROVE SURVIVAL ESTIMATIONS ON IMMATURE SURVIVAL DATA IN MULTIPLE MYELOMA (MM)

    Nov 1, 2019, 00:00

  • PRO56 ECONOMIC IMPACT OF THE INTRODUCTION OF RFVIII-SINGLECHAIN (AFSTYLA®) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY

    Nov 1, 2019, 00:00

  • PMS21 PRELIMINARY RESULTS OF A COST-UTILITY ANALYSIS OF A FRACTURE LIAISON SERVICE BASED ON HEALTH SERVICES INDICATORS

    Nov 1, 2019, 00:00

  • PMD60 AN INNOVATIVE REUSABLE ELECTRONIC INJECTION DEVICE FOR CERTOLIZUMAB PEGOL: RESULTS FROM A PILOT MARKET RESEARCH STUDY EXAMINING PATIENT PREFERENCE AND SATISFACTION

    Nov 1, 2019, 00:00

  • PMU85 LESSONS FOR BREAKING NEW GROUND WITH FIRST-IN-CLASS THERAPIES

    Nov 1, 2019, 00:00

  • Personalized Process of Care

    Nov 1, 2019, 00:00

  • PRO69 EPIDEMIOLOGICAL MODEL TO SUPPORT ORPHAN DESIGNATION DECISIONS: A DICE SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PCN340 FAST CHANGING APPROPRIATE COMPARATORS IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PCN200 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM MALIGNANT MELANOMA, A FINNISH REGISTRY STUDY

    Nov 1, 2019, 00:00

  • PND47 CLADRIBINE TABLET, AS A DOMINANT COMPARATOR TO NATALIZUMAB IN HIGH-DISEASE ACTIVITY RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN THE CONTEXT OF A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00

  • PNS229 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE ADDED MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE THROUGH EARLY ACCESS PROGRAM VS THE OTHERS

    Nov 1, 2019, 00:00

  • PNS3 COMPARISON OF FIVE METHODS FOR DOWNLOADING CONFERENCE ABSTRACTS: A CASE STUDY

    Nov 1, 2019, 00:00

  • PSY40 ASSESSING THE QUALITY AND COHERENCE OF NETWORK META-ANALYSES OF BIOLOGICS IN PLAQUE PSORIASIS: WHAT DOES ALL THIS EVIDENCE SYNTHESIS TELL US?

    Nov 1, 2019, 00:00

  • PND43 BUDGET IMPACT OF THE INTRODUCTION OF ALEMTUZUMAB IN NORWAY; A REAL WORLD EVIDENCE ANALYSIS USING DATA FROM THE NORWEGIAN PATIENT REGISTRY, THE NORWEGIAN PRESCRIPTION DATABASE, AND IMS SALES DATA

    Nov 1, 2019, 00:00

  • PMH32 THE ECONOMIC BURDEN OF ALCOHOL CONSUMPTION IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PRO97 VALUE ASSESSMENT FRAMEWORKS FOR ORPHAN DRUGS: A COMPARATIVE ANALYSIS ACROSS EUROPEAN JURISDICTIONS

    Nov 1, 2019, 00:00

  • PRS41 IDENTIFICATION OF POTENTIALLY UNDIAGNOSED PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE USING MACHINE LEARNING APPLIED TO PRIMARY CARE DATA IN UK

    Nov 1, 2019, 00:00

  • PNS288 ANALYSIS OF RECENT TRENDS IN E-HEALTH SOLUTIONS DEVELOPED BY PHARMACEUTICAL AND BIOTECH COMPANIES

    Nov 1, 2019, 00:00

  • PMD37 EVOLUTION OF UNION EUROPEAN MEDICAL DEVICE REGULATION: PERSPECTIVE WITH THE CLINICAL EVALUATION OF DUAL MOBILITY ACETABULAR CUPS BY THE FRENCH NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCY

    Nov 1, 2019, 00:00

  • PMU84 DRUG DECISION-MAKING PATHWAYS IN ENGLAND: CURRENT PROCESSES AND THE POTENTIAL IMPACT OF NICE CHANGES

    Nov 1, 2019, 00:00

  • PGI51 PSYCHOMETRIC EVALUATION OF NASH-CHECK, A PATIENT-REPORTED OUTCOME MEASURE FOR NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00

  • PCN20 ACCURATE PREDICTIONS OF LIFE YEAR GAINS FOR IMMUNO-ONCOLOGY THERAPIES IN THE LONG TERM? AN ANALYSIS BASED ON PUBLISHED CHECKMATE 057 NIVOLUMAB DATA

    Nov 1, 2019, 00:00

  • PIN49 BURDEN OF S. AUREUS, E. COLI, K. PNEUMONIAE ASSOTIATED INFECTIONS IN RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PMH64 PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA

    Nov 1, 2019, 00:00

  • PSS4 COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION (CNV) IN CHINA

    Nov 1, 2019, 00:00

  • PRO135 PROJECT HERCULES: A SYSTEMATIC REVIEW OF THE CONTENT AND STRUCTURAL VALIDITY OF PROS USED TO ASSESS QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00

  • PNS138 TRANSNATIONAL COLLABORATIONS AMONG DRUG REGULATORY AGENCIES: TRENDS AND FUTURE PERSPECTIVES

    Nov 1, 2019, 00:00

  • PND130 TREATMENT PATTERNS, HEALTH RESOURCES CONSUMPTION AND COSTS OF PATIENTS WITH MIGRAINE IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PCN469 DISEASE SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS FOR HEMATOLOGIC MALIGNANCIES (HM)

    Nov 1, 2019, 00:00

  • PCN222 CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE H ...

    Nov 1, 2019, 00:00

  • PCN486 REGULATORY SUCCESS IN LABELLING HRQOL AND SYMPTOMS FOR NSCLC THERAPIES

    Nov 1, 2019, 00:00

  • PIN2 EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. RESULTS IN REAL CLINICAL PRACTICE.

    Nov 1, 2019, 00:00

  • PDB26 THE BURDEN OF SEVERE HYPOPARATHYROIDISM IN GERMANY - A CLAIMS DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PIN71 PURSUING ELIMINATION OF HEPATITIS C IN EGYPT: AN ECONOMIC EVALUATION OF A COUNTRY-WIDE PROGRAM AND ITS ASSOCIATED COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PNS302 IMPROVING THE PERFORMANCE OF PATIENT-LEVEL SIMULATION MODELS USING MULTI-THREADING AND SINGLE INSTRUCTION MULTIPLE DATA (SIMD) OPERATIONS

    Nov 1, 2019, 00:00

  • PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY

    Nov 1, 2019, 00:00

  • PDG75 TRENDS IN THE USE OF PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS ARRANGEMENTS IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PRO46 EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PIN74 A NEW WAY TO INFORM DECISION-MAKER AND ENHANCE VACCINATION PROGRAMS IN COUNTRIES WITH LIMITED BUDGETS: THE CASE OF SERBIA

    Nov 1, 2019, 00:00

  • PIT2 PATTERNS OF OPIOID USE FOLLOWING FRACTURE BASED ON TIME BETWEEN PRESCRIPTION ORDER AND PATIENT FILL

    Nov 1, 2019, 00:00

  • PCV81 CURRENT TRENDS IN LIPID LOWERING THERAPY USE IN GERMANY

    Nov 1, 2019, 00:00

  • PGI3 DEPRESCRIBING OF LONG TERM UTILIZATION OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS BASED ON ENDOSCOPIC ANALYSIS

    Nov 1, 2019, 00:00

  • PND51 PRODUCTIVITY LOSS IN NHS HOSPITALS DUE TO DIFFICULT-TO-TREAT MIGRAINE

    Nov 1, 2019, 00:00

  • PCV14 COMPARATIVE EFFECTIVENESS AND SAFETY OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN184 ECONOMIC EVALUATION OF CHECKPOINT INHIBITORS FOR THE TREATMENT OF ADVANCED MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PCN50 INDIRECT COMPARISON OF PARP INHIBITORS IN OVARIAN CANCER: NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PDB9 SERUM GGT AND HSCRP: EARLY PREDICTORS OF OXIDATIVE STRESS AND INFLAMMATION IN TYPE 2 DIABETES MELLITUS PATIENTS WITH GOOD AND POOR GLYCEMIC CONTORL

    Nov 1, 2019, 00:00

  • PRO11 FACTORS ASSOCIATED WITH BLEEDING EXPERIENCE IN HEMOPHILIA A PATIENTS IN SOUTH KOREA

    Nov 1, 2019, 00:00

  • PCN524 EUROPEAN REAL-WORLD TREATMENT PATTERNS OF SYSTEMIC THERAPIES FOR SECOND LINE (2L) HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO PREVIOUSLY RECEIVED SORAFENIB

    Nov 1, 2019, 00:00

  • PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY

    Nov 1, 2019, 00:00

  • PCN306 THE MODEL OF OUTCOMES-BASED RISK SHARING AGREEMENTS APPLIED TO TARGETED DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • AI4 GENERAL PAIRWISE COMPARISONS TO SUPPORT QUANTITATIVE MULTIPLE CRITERIA DECISION ANALYSIS

    Nov 1, 2019, 00:00

  • PMS51 TRAJECTORIES OF FOLLOW-UP COMPLIANCE AND THEIR PREDICTORS IN A FRACTURE LIAISON SERVICE

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Organizational Practices

    Nov 1, 2019, 00:00

  • PDG2 METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN PATIENTS RECEIVING PALLIATIVE CARE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL

    Nov 1, 2019, 00:00

  • PCN255 ESTIMATION OF THE POTENTIAL IMPACT OF THE FRENCH CRC SCREENING PROGRAM BASED ON REAL-WORLD PARTICIPATION RATES

    Nov 1, 2019, 00:00

  • PDB69 ECONOMIC BURDEN OF TYPE 2 DIABETES (T2D) IN EMERGING AND ESTABLISHED MARKETS: DATA FROM THE G15 REVIEW

    Nov 1, 2019, 00:00

  • PNS343 THE COMPLETENESS OF CLINICALTRIALS.GOV. - WHAT IS THE RATE OF PUBLISHED CLINICAL TRIALS REGISTERED ON THE WEBSITE?

    Nov 1, 2019, 00:00

  • PRO161 EPIDEMIOLOGY, HEALTHCARE RESOURCE CONSUMPTION AND RELATED COSTS FOR HYPOPHOSPHATEMIC VITAMIN D RESISTANT RICKETS PATIENTS IN AN ITALIAN REGION

    Nov 1, 2019, 00:00

  • PND65 FILLING THE GAP IN MS; UNIQUE IDENTIFICATION OF PREVALANCE TREATMENT OF SPMS PATIENTS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    Nov 1, 2019, 00:00

  • PMH66 COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HCRU) AND EXPENDITURES AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MEDICATION-ASSISTED TREATMENT (MAT) RECEIVED

    Nov 1, 2019, 00:00

  • PIT5 EXPERIENCE OF 2 INSTITUTIONS WITH THE GERIATRIC FRACTURE PROGRAM IN COLOMBIA: LENGTH OF STAY, MORTALITY AND ESTIMATION OF COSTS

    Nov 1, 2019, 00:00

  • PNS87 IMPACT OF SELF SUSTAINABLE SYSTEM FOR SAFE DRUG DISPOSAL: A FOLLOW UP STUDY

    Nov 1, 2019, 00:00

  • PNS150 CONDITIONAL MARKETING AUTHORISATION FOR NOVEL TREATMENTS: A LANDSCAPE ASSESSMENT OF EXPEDITED PATHWAYS OUTSIDE US AND EU

    Nov 1, 2019, 00:00

  • PIN114 UNDERSTANDING CHANGES IN FULL CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA BETWEEN 2000 AND 2016: OAXACA-BLINDER DECOMPOSITION ANALYSIS

    Nov 1, 2019, 00:00

  • PDB61 THE CLINICAL AND ECONOMIC IMPACT OF ADDING AN ADHERENCE MODULE TO THE IQVIA CORE DIABETES MODEL

    Nov 1, 2019, 00:00

  • PSY45 PATIENT-REPORTED OUTCOMES USED IN CLINICAL TRIALS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A REVIEW OF SUITABILITY FOR FDA LABELLING CLAIMS

    Nov 1, 2019, 00:00

  • PDB38 COST OF ANTI-DIABETIC MEDICATIONS AMONG TYPE II DIABETES MELLITUS PATIENTS: A CROSS-SECTIONAL STUDY IN SOUTH INDIA

    Nov 1, 2019, 00:00

  • PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PNS358 DEVELOPMENT AND OPTIMIZATION OF NATIONWIDE INTEROPERABLE CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) IN KOREA

    Nov 1, 2019, 00:00

  • PDB33 COST-EFFECTIVENESS OF THE PDM-PROVALUE STUDY PROGRAM IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM THE GERMAN STATUTORY HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN305 FUNDING TRENDS FOR IN-HOSPITAL DRUGS: GERMAN NUB ANALYSIS

    Nov 1, 2019, 00:00

  • PIN64 COST OF HEPATITIS C VIRUS ERADICATION: ECONOMIC MODEL CONCEPT

    Nov 1, 2019, 00:00

  • PSU27 ANALYSIS OF THE UTILIZATION OF ONE-DAY SURGERY AMONG CASES RELATED TO THE DISEASES OF THE MUSCULOSKELETAL SYSTEM OR CONNECTIVE TISSUE

    Nov 1, 2019, 00:00

  • PMD24 ECONOMIC EVALUATION OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN TAIWAN

    Nov 1, 2019, 00:00

  • PR2 FATIGUE: ITS USE ACROSS TRIALS FOR MULTIPLE CONDITIONS: REGULATORY SUCCESS

    Nov 1, 2019, 00:00

  • PCN258 APPLYING BIG DATA ANALYTICS TO DEVELOP PREDICTIVE MODELS FOR ESTIMATING HER2+ BC INCIDENCE AND PREVALENCE IN BRAZIL

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PSY10 PRIMARY SJOGREN'S SYNDROME: A RETROSPECTIVE COHORT STUDY OF BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2019, 00:00

  • PNS112 PHARMACIST’S PRIVILEGE IN SAUDI ARABIA: PHARMACIST PRESCRIBING AND THERAPEUTIC INTERCHANGE

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PPM5 COSTS OF IN-HOUSE MUTATIONAL-TESTING AND IMPLICATIONS FOR ECONOMIC EVALUATION: A CASE EXAMPLE OF NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PMH25 ASSOCIATION OF ADOLESCENT DEPRESSION WITH EARNINGS IN ADULTHOOD

    Nov 1, 2019, 00:00

  • PMD15 COST EFFECTIVENESS ANALYSIS OF STANDARD AND PREMIUM INTRAOCULAR LENSES IMPLEMENTED IN THE TREATMENT OF CATARACT UNDER DIFFERENT INSURANCE SCHEMES IN EGYPT

    Nov 1, 2019, 00:00

  • PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN219 WHAT IS WORTH KNOWING AT EARLY DEVELOPMENT? VALUE OF INFORMATION ANALYSIS USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A CASE STUDY

    Nov 1, 2019, 00:00

  • PRO45 NATIONAL BURDEN OF HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00

  • PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN18 CLINICAL BENEFITS OF REHABILITATION IN PATIENTS WITH ADVANCED CANCER IN KOREA

    Nov 1, 2019, 00:00

  • PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PND53 ECONOMIC EVALUATION OF CLADRIBINE TABLETS IN RELAPSING MULTIPLE SCLEROSIS (RMS) PATIENTS WITH HIGH DISEASE ACTIVITY (HDA) IN LEBANON

    Nov 1, 2019, 00:00

  • PMU62 ASSESSING WHETHER PRODUCTS NEED TO BE COST-SAVING IN ORDER TO GAIN ACCELERATED ACCESS COLLABORATIVE RAPID UPTAKE STATUS IN NHS ENGLAND

    Nov 1, 2019, 00:00

  • PDG78 IMPACT OF FIRST RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) FROM EUNETHTA ON DRUG HTA ASSESSMENTS BY HAS, IQWIG AND NICE

    Nov 1, 2019, 00:00

  • PMU6 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 5% LIDOCAINE-MEDICATED PLASTER VS. PREGABALIN

    Nov 1, 2019, 00:00

  • PSY49 THE JOURNEY OF THALASSAEMIA PATIENT IN SEEKING TREATMENT IN MALAYSIAN HEALTHCARE

    Nov 1, 2019, 00:00

  • PND36 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN285 THERAPEUTIC BENEFIT OF ORPHAN DRUGS IN ONCOLOGY: EVIDENCE AT THE POINT OF EUROPEAN MARKETING AUTHORISATION

    Nov 1, 2019, 00:00

  • PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PNS63 WILLINGNESS TO PAY FOR HEALTH INSURANCE USING THE CONTINGENT VALUATION METHOD: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIN145 PATIENT PREFERENCES TOWARDS DRUG TREATMENT OF CHRONIC HEPATITIS B - A DISCRETE CHOICE EXPERIMENT IN GERMANY

    Nov 1, 2019, 00:00

  • PUK39 URINARY TRACT INFECTIONS (UTIS) AFTER UROGENITAL PROCEDURES AND RELATED OUTCOMES AND COSTS: ANALYSIS OF DATA FROM THE NATIONAL HOSPITAL INFORMATION SYSTEM

    Nov 1, 2019, 00:00

  • CC2 ECONOMIC ASSESSMENT OF A HIGH DOSE VERSUS A STANDARD DOSE INFLUENZA VACCINE IN THE US VETERAN POPULATION: ESTIMATING THE IMPACT ON HOSPITALIZATION COST FOR CARDIOVASCULAR AND RESPIRATORY DISEASE

    Nov 1, 2019, 00:00

  • PMU40 NEWLY DIAGNOSED DEPRESSION AND DEPRESSION SEVERITY AMONG WOMEN WITH INCIDENT BREAST CANCER

    Nov 1, 2019, 00:00

  • PCN350 CLINICAL AND ECONOMIC ASSESSMENT OF THE IMPORTANCE OF SUPPORTIVE THERAPY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN269 INCIDENCE OF FECAL AND URINARY INCONTINENCE IN PATIENTS WITH A DIAGNOSIS OF RECTAL CARCINOMA

    Nov 1, 2019, 00:00

  • PUK9 MEDICO-ECONOMIC EVALUATION OF HAEMODIAFILTRATION IN COMPARISON TO HIGH FLUX DIALYSIS

    Nov 1, 2019, 00:00

  • PDB49 THE RELATIONSHIP BETWEEN HBA1C REDUCTION AND COSTS: A COHORT STUDY OF PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PRO9 A SYSTEMATIC REVIEW OF THE CLINICAL BURDEN OF IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE

    Nov 1, 2019, 00:00

  • PMH69 RISING DEPENDENCE ON ANTI-DEPRESSANTS AMONG ADULTS IN US: A STUDY BASED ON NHANES FROM 2005 TO 2016

    Nov 1, 2019, 00:00

  • PNS311 PREDICTIVE-ADJUSTED INDIRECT COMPARISON (PAIC): A NOVEL METHOD FOR POPULATION-ADJUSTED INDIRECT COMPARISON

    Nov 1, 2019, 00:00

  • PCN203 HEALTH-CARE RESOURCE USE AND COSTS IN AML-PATIENTS UNDERGOING STEM CELL TRANSPLANTATION

    Nov 1, 2019, 00:00

  • PNS126 NEW DRUG BUDGET AND REIMBURSEMENT POLICY IN TAIWAN

    Nov 1, 2019, 00:00

  • PRO71 WHAT WAS THE ACTUAL BUDGET IMPACT OF ORPHAN MEDICINAL PRODUCTS BETWEEN 2000-2017 IN EUROPE?

    Nov 1, 2019, 00:00

  • PCN193 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

    Nov 1, 2019, 00:00

  • PNS58 ANALYSIS OF FINANCIAL STATUS AND DETERMINANTS WITH ALTMAN'S Z-SCORE MODEL: A PANEL DATA INVESTIGATION FROM TRADITIONAL CHINESE MEDICINE LISTED COMPANIES IN CHINA

    Nov 1, 2019, 00:00

  • PCV86 ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY WITH CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY IN POST-MI PATIENTS IN GERMANY.

    Nov 1, 2019, 00:00

  • PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?

    Nov 1, 2019, 00:00

  • PDB72 DEPRIVATION - MAIN CAUSE OF DIABETIC FOOT ULCER IN GERMANY

    Nov 1, 2019, 00:00

  • PNS145 THE MALTESE EXCEPTIONAL MEDICINAL TREATMENT ROUTE: A BYPASS TO HEALTHCARE?

    Nov 1, 2019, 00:00

  • PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY

    Nov 1, 2019, 00:00

  • PRO143 PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

    Nov 1, 2019, 00:00

  • PMU100 A SYSTEMATIC REVIEW OF PREVIOUSLY PUBLISHED OR APPRAISED HEALTH ECONOMIC ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00

  • PND125 PREGABALIN PRESCRIBING IN PRIVATE HEALTHCARE SETTINGS IN SOUTH AFRICA WITH SPECIFIC FOCUS ON DOSAGES

    Nov 1, 2019, 00:00

  • PCN22 BURDEN OF BRAIN METASTASES (BM) IN ALK+ NON-SMALL CELL LUNG CANCER (ALK+ NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

    Nov 1, 2019, 00:00

  • PSU10 ECONOMIC EVALUATION OF HYSTERECTOMY IN THE REAL CLINICAL PRACTICE: ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC

    Nov 1, 2019, 00:00

  • PNS140 POTENTIAL IMPACTS OF THE U.K. VOLUNTARY SCHEME FOR BRANDED MEDICINES PRICING AND ACCESS: A REVIEW OF STAKEHOLDER OPINION

    Nov 1, 2019, 00:00

  • PSU18 THE COST-EFFECTIVENESS OF ENOXAPARIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR SURGERY IN EGYPT

    Nov 1, 2019, 00:00

  • PIT15 INTRAMEDULLARY NAILING OF HUMERAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00

  • PCN48 FEASIBILITY OF EXTRACTING SURVIVAL DATA FROM PUBLISHED LITERATURE USING THE GUYOT ALGORITHM

    Nov 1, 2019, 00:00

  • PMU43 A MORE ACCURATE MEASURE OF AFFORDABILITY OF ALCOHOL FOR THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PMU13 COST-EFFECTIVENESS ANALYSIS OF PCT-GUIDED ANTIBIOTIC STEWARDSHIP FOR HOSPITALIZED PATIENTS WITH SEPSIS OR LOWER RESPIRATORY TRACT INFECTIONS IN A US HOSPITAL

    Nov 1, 2019, 00:00

  • PMU34 COMPARATIVE ANALYSIS OF DISABILITY ADJUSTED LIFE YEARS FROM ADVERSE EFFECTS OF MEDICAL TREATMENT IN UKRAINE AND OTHER COUNTRIES

    Nov 1, 2019, 00:00

  • PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL

    Nov 1, 2019, 00:00

  • PNS91 ACCESS AND UTILIZATION OF MATERNAL HEALTHCARE IN A RURAL DISTRICT IN THE FOREST BELT OF GHANA

    Nov 1, 2019, 00:00

  • PCN85 COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PND50 ECONOMIC BURDEN OF ALZHEIMER'S DISEASE DEMENTIA IN JAPAN

    Nov 1, 2019, 00:00

  • PCN101 COST-EFFECTIVENESS ANALYSIS OF TORIPALIMAB VERSUS PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA IN CHINA

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Patient-Centered Research

    Nov 1, 2019, 00:00

  • Mental Health - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PIN86 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH VARYING COVERAGE OF VARICELLA VACCINATION STRATEGIES IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PNS365 THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PRO115 DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

    Nov 1, 2019, 00:00

  • PCV57 STUDY ON THE ATTRIBUTABLE COSTS OF VENOUS THROMBOEMBOLISM AND BLEEDINGS IN DENMARK. COMPARISON OF THE DIFFERENCE-IN-DIFFERENCE AND THE DIFFERENCE-IN-ACTUAL-COSTS METHODS

    Nov 1, 2019, 00:00

  • PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY

    Nov 1, 2019, 00:00

  • PDB102 TARGETED LITERATURE REVIEW INTO METHODS OF DETERMINING PATIENTS' PREFERENCE FOR TREATMENT TYPE IN DIABETES

    Nov 1, 2019, 00:00

  • PRS21 PRODUCTIVITY LOSSES FOR ALLERGIC RHINITIS PATIENTS IN THE NETHERLANDS AND SWEDEN

    Nov 1, 2019, 00:00

  • Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions [Editor's Choice]

    Nov 1, 2019, 00:00

  • PNS384 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURED BY PROMIS PREFERENCE SCORE (PROPR) IN THE GENERAL POPULATION OF THE UNITED KINGDOM, FRANCE, AND GERMANY

    Nov 1, 2019, 00:00

  • The Joint Committee on Vaccination and Immunisation’s Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?

    Nov 1, 2019, 00:00

  • PNS57 BUDGET IMPACT ANALYSIS OF A WEARABLE REMOTE CONTINUOUS MONITORING DEVICE TO FACILITATE EARLY DISCHARGE OF BARIATRIC SURGERY PATIENTS IMMEDIATELY AFTER POSTOPERATIVE OBSERVATION IN THE RECOVERY WARD

    Nov 1, 2019, 00:00

  • PDG107 DRUG SURVIVAL OF BIOLOGICAL THERAPIES FOR ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE

    Nov 1, 2019, 00:00

  • PRO26 THE NICE APPRAISAL OF BUROSUMAB FOR THE TREATMENT OF XLH: EVALUATING THE LIFELONG OUTCOMES AND COST-EFFECTIVENESS OF CORRECTING DEFORMITY WHEN TREATING CHILDREN AND ADOLESCENTS WITH A GROWING SKELETON

    Nov 1, 2019, 00:00

  • PBI75 REVIEW OF ECONOMIC EVALUATIONS FOR GENE THERAPIES:ARE WE READY FOR THE FUTURE?

    Nov 1, 2019, 00:00

  • PCN338 KEY DRIVERS OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR RELAPSED-REFRACTORY MULTIPLE MYELOMA TREATMENTS; A COUNTRY COMPARISON.

    Nov 1, 2019, 00:00

  • PCN195 COST COMPARISON BETWEEN LEUPROLIDE 3-MONTH FORMULATION AND GOSERELIN 1-MONTH FORMULATION AS ADJUVANT ENDOCRINE THERAPY IN POST-MASTECTOMY, PREMENOPAUSAL WOMEN WITH EARLY-STAGE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER WHO ARE AT MODE ...

    Nov 1, 2019, 00:00

  • PNS143 PRIORITIZATION OF DRUGS FOR REIMBURSEMENT IN THE MALTESE HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PSU40 PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL JOINT REPLACEMENT: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG25 ECONOMIC BURDEN OF OPIOID ABUSE IN THE USA

    Nov 1, 2019, 00:00

  • PNS73 WHAT IS THE VALUE FOR A QALY IN FRANCE?

    Nov 1, 2019, 00:00

  • PCN177 ORGANIZATIONAL AND ECONOMIC IMPACT OF NEXT GENERATION SEQUENCING AND HOTSPOT APPROACH

    Nov 1, 2019, 00:00

  • PAM15 PHOTOGRAPHIC FOOD DIARIES FOR NUTRITIONAL RESEARCH WITH CHILDREN AND HARD-TO-REACH POPULATIONS: A CASE STUDY EXPLORATION OF A NOVEL ASSESSMENT TOOL

    Nov 1, 2019, 00:00

  • PMD47 BREAKAGE OF INTRAMEDULLARY NAILING IN TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES

    Nov 1, 2019, 00:00

  • PNS289 EVALUATION OF THE SAFETY AND EFFICACY OF AI FOR DETECTION OF CHRONIC NON-COMMUNICABLE DISEASES IN REMOTE AREAS

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Organizational Practices

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS88 THE "REHAB MAP” FOR INTERACTIVE PLANNING OF AMBULATORY REHABILITATION SERVICES

    Nov 1, 2019, 00:00

  • PNS11 EARLY HEALTH ECONOMIC MODELLING AS A TOOL TO GUIDE STRATEGIC CLINICAL DEVELOPMENT AND IN-LICENSING DECISIONS

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS350 ANALYSIS OF HEALTH CARE WORKERS' MIGRATION: THE MOTIVATIONS OF HUNGARIAN PHISIOTHERAPISTS FOR WORKING ABROAD

    Nov 1, 2019, 00:00

  • PNS361 THE TSQM: 15 YEARS OF USE

    Nov 1, 2019, 00:00

  • PDB131 THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND

    Nov 1, 2019, 00:00

  • PCN268 ESTIMATING THE BURDEN OF MALIGNANT HAEMATOPOIETIC CANCERS IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00

  • PCN234 COST-EFFECTIVENESS ANALYSIS OF HOME-BASED PALLIATIVE CARE FOR END-STAGE CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PCV78 BURDEN OR ATRIAL FIBRILLATION AND BUDGET IMPACT OF DABIGATRAN IN ALGERIA

    Nov 1, 2019, 00:00

  • PCN9 TREATMENT PATTERNS AND SURVIVAL IN UNRESECTABLE ADVANCED ESOPHAGEAL SQUAMOUS CELL CANCER IN THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) MEDICARE LINKED DATA

    Nov 1, 2019, 00:00

  • PDB109 BURDEN OF ILLNESS ASSOCIATED WITH HYPERPHAGIA AND SEVERE OBESITY

    Nov 1, 2019, 00:00

  • PCN411 HOW ARE SINGLE-ARM TRIALS PERCEIVED IN HEATH TECHNOLOGY ASSESSMENTS FOR CHRONIC LEUKAEMIA ACROSS THE EU5, AUSTRALIA AND CANADA?

    Nov 1, 2019, 00:00

  • PNS275 SHOULD LIFECYCLE PRICING BE CONSIDERED IN HTA? PRACTICAL CONSIDERATIONS FOR INCORPORATION INTO HTA POLICY

    Nov 1, 2019, 00:00

  • Neurological Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PNS218 SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: ESTABLISHING A EUROPEAN PICO

    Nov 1, 2019, 00:00

  • PCV61 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN TURKEY

    Nov 1, 2019, 00:00

  • PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB10 COST ASSOCIATED WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS IN TWO TERTIARY HEALTHCARE FACILITIES IN A RESOURCE-LIMITED SETTING

    Nov 1, 2019, 00:00

  • CP3 DEVELOPING PROCESSES AND METHODS FOR A EUROPEAN COLLABORATION ON HTA: ACHIEVEMENTS, CHALLENGES AND LESSONS LEARNT

    Nov 1, 2019, 00:00

  • PCN324 PRELIMINARY EVIDENCE SUGGESTS THAT WE MOVE TOWARDS THE USE OF LIQUID BIOPSIES TO PREDICT RESPONSE TO TKI INHIBITORS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges

    Nov 1, 2019, 00:00

  • PRO128 AN EVIDENCE-BASED APPROACH TO PREDICT LONG-TERM PATIENT OUTCOMES IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

    Nov 1, 2019, 00:00

  • PCN51 OUTCOMES MANAGEMENT IN A REAL WORLD EVIDENCE CONTEXT. THE CASE OF ABIRATERONE AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PIN43 LIFECYCLE-MODEL-BASED ECONOMIC EVALUATION OF INFANT MENINGITIS B VACCINATION IN THE UK

    Nov 1, 2019, 00:00

  • PDB112 EXPERIENCES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS PATIENTS IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PCN412 COMPARING THE LONG-TERM SURVIVAL METHODOLOGIES IN PHARMACOECONOMIC MODELS OR GLIOBLASTOMA: WHICH BEST REFLECT REAL-WORLD OUTCOMES?

    Nov 1, 2019, 00:00

  • PRS72 DRUG TREATMENT PATTERNS FOR PULMONARY ARTERIAL HYPERTENSION PATIENTS IN ENGLAND: A RETROSPECTIVE ANALYSIS USING HOSPITAL TREATMENT INSIGHTS DATABASE

    Nov 1, 2019, 00:00

  • PCN144 ECONOMIC EVALUATIONS OF CANCER INTERVENTIONS IN SPAIN: LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PBI28 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Nov 1, 2019, 00:00

  • PCV87 A REVIEW ASSESSING THE PROPORTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS AMONGST HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00

  • PMS13 EXPERIMENTAL STUDY OF TOPICAL TREATMENT OF RHEUMATOID ARTHRITIS WITH TNF-Α ANTAGONIST

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • Surgery - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PSY16 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

    Nov 1, 2019, 00:00

  • PCN364 REIMBURSEMENT OF CAR-T CELL THERAPY IN THE UK, A STEP TOWARDS MORE PERSONALISED CANCER TREATMENT

    Nov 1, 2019, 00:00

  • PCN485 PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3 MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

    Nov 1, 2019, 00:00

  • PCN174 BUDGET IMPACT OF LEUPROLIDE ACETATE 3-MONTHLY DEPOT FORMULATIONS FOR THE MANAGEMENT OF PATIENTS WITH ADVANCED AND METASTATIC PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PIN94 HUMAN PAPILLOMAVIRUS (HPV) VACCINE COVERAGE RATES (VCR) IN FRANCE: A FRENCH CLAIMS DATA STUDY

    Nov 1, 2019, 00:00

  • PCN494 POTENTIAL USE OF ARTIFICIAL INTELLIGENCE TO ANALYZE DATA EXTRACTED FROM ELECTRONIC HEALTH RECORDS FOR DECISION ANALYTIC MODELS

    Nov 1, 2019, 00:00

  • Surgery - Medical Technologies

    Nov 1, 2019, 00:00

  • PIN48 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA

    Nov 1, 2019, 00:00

  • PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?

    Nov 1, 2019, 00:00

  • PCN458 ATTITUDE TOWARDS PARTICIPATION ON BREAST CANCER SCREENING AND THE ASSESSMENT OF INFLUENCING FACTORS AMONG 45-65 YEARS OLD WOMEN

    Nov 1, 2019, 00:00

  • PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...

    Nov 1, 2019, 00:00

  • PCV56 COST-EFFECTIVENESS OF THE SUSTAINED-RELEASE PACLITAXEL-ELUTING ELUVIA STENT COMPARED TO THE PACLITAXEL-COATED ZILVER PTX STENT FOR ENDOVASCULAR TREATMENT OF PERIPHERAL ARTERY DISEASE: A GERMAN STATUTORY SICKNESS FUND PERSPECTIVE.

    Nov 1, 2019, 00:00

  • PDG99 PATIENT'S PREFERENCES REGARDING DIRECT ORAL ANTICOAGULANTS SELECTION: RELEVANT CRITERIA FOR ROUTINE CLINICAL DECISION MAKING?

    Nov 1, 2019, 00:00

  • PNS250 CADTH PARALLEL SCIENTIFIC ADVICE PROGRAMS WITH NICE AND HEALTH CANADA

    Nov 1, 2019, 00:00

  • PUK3 TREATMENT EFFECTS IN SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN506 MUTATION TESTING AND TREATMENT OF THE MOST COMMON ONCOLOGY DISEASES IN GERMANY: ANALYSIS OF AN ONCOLOGY EMR DATABASE

    Nov 1, 2019, 00:00

  • PCN205 COMPARISON OF METHODS TO ACCOUNT FOR CURED PATIENTS IN A COST-EFFECTIVENESS ANALYSIS: A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PNS368 THE EVOLVING ROLE OF PATIENT ADVOCACY IN DRUG APPRAISAL AND COMMISSIONING: PERSPECTIVES FROM ENGLAND

    Nov 1, 2019, 00:00

  • PCN331 HUMANISTIC BURDEN OF NEWLY DIAGNOSED VERSUS RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00

  • PNS236 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE IN EARLY ACCESS PROGRAM VS THE OTHERS IN FRANCE

    Nov 1, 2019, 00:00

  • PSU16 ESTIMATING THE CLINICAL AND ECONOMIC IMPACT OF IMPLEMENTING PREOPERATIVE ANEMIA MEASURES IN THE GERMAN HEALTHCARE SYSTEM: THE HEALTH ECONOMIC FOOTPRINT OF PATIENT BLOOD MANAGEMENT (PBM)

    Nov 1, 2019, 00:00

  • PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PDB56 ECONOMIC IMPACT OF TYPE 2 DIABETES AND DIABETES-ASSOCIATED COMPLICATIONS: A LARGE CLAIMS-BASED STUDY

    Nov 1, 2019, 00:00

  • PCN434 THE EFFECT MODIFICATION PROBLEM: USING STRATIFIED MATCHING ADJUSTED INDIRECT COMPARISON TO EVADE MISLEADING INTERPRETATIONS OF THE TREATMENT EFFECT

    Nov 1, 2019, 00:00

  • PBI14 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS AND APREMILAST IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS374 CLINICAL BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN CAREGIVERS OF CANCER PATIENTS: RESULTS FROM LINKING ELECTRONIC HEALTH RECORDS TO PATIENT-REPORTED OUTCOMES

    Nov 1, 2019, 00:00

  • PCN278 EXPLORING PRE AND POST AGENZIA ITALIANA DEL FARMACO (AIFA) REIMBURSED ACCESS TO IMMUNOTHERAPY FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00

  • PCV37 BUDGET IMPACT ANALYSIS OF ANTIPLATELET THERAPY WITH CANGRELOR IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SPAIN

    Nov 1, 2019, 00:00

  • PSU15 COST-EFFECTIVENESS OF SHOULDER ARTHROPLASTY: A PROSPECTIVE STUDY USING REAL-WORLD DATA FROM SWITZERLAND

    Nov 1, 2019, 00:00

  • PRS5 TREATMENT PERSISTENCE AND EXACERBATIONS IN PATIENTS WITH ASTHMA INITIATING TREATMENT WITH INHALED CORTICOSTEROIDS AND LONG-ACTING BETA-ADRENERGIC AGONISTS (ICS/LABA): REAL-LIFE STUDY

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PSS22 FACTORS INFLUENCING AGREEMENT BETWEEN PATIENT AND CLINICIAN ASSESSMENTS OF SEVERITY IN CHRONIC PLAQUE PSORIASIS

    Nov 1, 2019, 00:00

  • PND68 ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION AND PARKINSON'S DISEASE IN PATIENTS FOLLOWED BY GENERAL PRACTITIONERS IN GERMANY

    Nov 1, 2019, 00:00

  • PCV90 RISK FACTORS, USE OF HEALTH CARE RESOURCES, AND MORTALITY IN PATIENTS WITH MINOR ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK

    Nov 1, 2019, 00:00

  • PMD3 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM BEARING SURFACE IN HIP REPLACEMENT 90-DAY EPISODE CLAIMS

    Nov 1, 2019, 00:00

  • PNS323 WHAT IS A VALID MAPPING ALGORISM IN COST-UTILITY ANALYSES? AN ANSWER FROM A MISSING DATA PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIH29 SELF- MEDICATION: ASSESSMENT OF PRACTICES AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00

  • PDB45 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): RESOURCE USE AND DIRECT COSTS

    Nov 1, 2019, 00:00

  • PCV21 TIMI RISK SCORE IN PREDICTING IN HOSPITAL AND EARLY MORTALITY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY WOMEN:RESULTS FROM A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00

  • PBI13 TNF-ALPHA INHIBITORS IN THE CZECH REPUBLIC: HOW BIOSIMILARS AFFECT OVERALL CONSUMPTION AND COSTS?

    Nov 1, 2019, 00:00

  • PCN481 METHODOLOGICAL ASPECTS OF HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER IN CLINICAL TRIALS: A SYSTEMATIC REVIEW.

    Nov 1, 2019, 00:00

  • Real World DATA Information Systems

    Nov 1, 2019, 00:00

  • PDG54 INTERNATIONAL COMPARISON OF ORPHAN DRUG POLICY EFFECT ON ORPHAN DRUG EXPENDITURE

    Nov 1, 2019, 00:00

  • PBI8 UNKNOWN

    Nov 1, 2019, 00:00

  • PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

    Nov 1, 2019, 00:00

  • PUK15 INPATIENT COST-SAVINGS FROM THE USE OF SUCROFERRIC OXYHYDROXIDE IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN423 MEASURING FATIGUE SYMPTOMS AND IMPACTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): EVALUATING DIMENSIONALITY OF THE FACIT-FATIGUE

    Nov 1, 2019, 00:00

  • PMU61 IDENTIFYING DISEASE AREAS WHERE DISRUPTIVE INNOVATION IS LIKELY TO HAVE A SIGNIFICANT IMPACT ON HEALTHCARE SYSTEMS AND BUDGETS. THE IMPORTANCE OF TRACKING PAYER BEHAVIOURS

    Nov 1, 2019, 00:00

  • PNS396 VALUING HEALTH RELATED QUALITY OF LIFE IN MOROCCO: AN EQ-5D-3L VALUE SET

    Nov 1, 2019, 00:00

  • PDG27 ARE ACUTE THERAPIES AND CURATIVE DRUGS MORE AFFORDABLE THAN CHRONIC TREATMENTS IN RARE DISEASES? AN ANALYSIS OF THE TOP 20 MOST EXPENSIVE DRUGS IN THE US

    Nov 1, 2019, 00:00

  • PMU148 CUTANEOUS LYMPHOMAS IN GERMANY: LANDSCAPING ANALYSIS OF GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN337 HTA DECISIONS IN FRANCE AND GERMANY: LESSONS FROM MELANOMA

    Nov 1, 2019, 00:00

  • PCN503 USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM TREATMENT DECISIONS AMONG US ONCOLOGISTS

    Nov 1, 2019, 00:00

  • RARE Information Systems

    Nov 1, 2019, 00:00

  • PNS61 DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE?

    Nov 1, 2019, 00:00

  • PND7 EFFICACY OF VIRTUAL REALITY GLASSES AMONG PATIENTS WITH STROKE

    Nov 1, 2019, 00:00

  • PCN55 NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2- ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY

    Nov 1, 2019, 00:00

  • Injury Trauma - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIN80 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT PATHOGENS ASSOCIATED WITH HEALTHCARE-ASSOSIATED INFECTIONS: A BUDGET IMPACT ANALYSIS IN ARGENTINA

    Nov 1, 2019, 00:00

  • PNS380 BREAST CANCER PATIENT PERSPECTIVES ON IMPORTANT SYMPTOM INFORMATION

    Nov 1, 2019, 00:00

  • PNS359 INTERNATIONAL OBSERVATIONAL STUDIES: THE INCREASED NEED FOR A COMMON EUROPEAN REGULATION

    Nov 1, 2019, 00:00

  • PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE

    Nov 1, 2019, 00:00

  • PCN358 COMPARING AND VALIDATING THE OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TREATMENTS APPLIED IN HTA'S BY NOMA AND TLV

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PRO29 COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING

    Nov 1, 2019, 00:00

  • PND133 IMPACT OF CLINICAL COMPLICATIONS ON ECONOMIC BURDEN IN NEWLY DIAGNOSED PARKINSON POPULATION USING A US CLAIM DATABASE

    Nov 1, 2019, 00:00

  • PNS21 REAL WORLD EVIDENCE (RWE) IN PARTITION SURVIVAL MODELLING: IS IT THE REAL DEAL?

    Nov 1, 2019, 00:00

  • Infectious Disease Studies

    Nov 1, 2019, 00:00

  • PCN165 A GERMAN COST ANALYSIS OF TRIPLET REGIMENS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PNS97 GEOGRAPHIC DIFFERENCES IN IRISH HEALTH STATUS

    Nov 1, 2019, 00:00

  • PNS173 MEASURING DELAYS IN THE AVAILABILITY OF NEW MEDICINES WITHIN EUROPE USING A TIME-TO-PRICE INDICATOR

    Nov 1, 2019, 00:00

  • PNS309 UTILIZING MACHINE LEARNING AND ECG DATA FOR CONTINUOUS USER AUTHENTICATION OF PATIENTS DURING A CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • PCV117 DESIGNING THE NEXT TRIAL FROM NETWORK META-ANALYSES USING SIMULATION-BASED ASSURANCE CALCULATIONS

    Nov 1, 2019, 00:00

  • PIN136 MODELLING CD4 TRANSITIONS IN HIV PATIENTS: VALIDATING A MARKOV MODEL BASED APPROACH

    Nov 1, 2019, 00:00

  • RARE Regulatory

    Nov 1, 2019, 00:00

  • PBI46 IMPLEMENTATION OF ADALIMUMAB BIOSIMILARS IN DENMARK

    Nov 1, 2019, 00:00

  • PNS392 THE ROLE OF PATIENTS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS AS PERCEIVED BY PROFESSIONALS

    Nov 1, 2019, 00:00

  • PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PNS163 SHIFTING PARADIGM OF INTERNATIONAL REFERENCE PRICING. IS IT BENEFICIAL TO PAYERS, MANUFACTURERS OR PATIENTS?

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PMS23 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ANKLE AND FOOT IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PUK18 THE ECONOMIC COST ASSOCIATED WITH NOCTURIA IN A WORKING-AGE POPULATION

    Nov 1, 2019, 00:00

  • Alternative Medicine Public Health

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS336 NETWORK META-ANALYSIS (NMA) WITH TIME-VARYING HAZARD: A COMPARATIVE ANALYSIS OF SURVIVAL OUTCOMES

    Nov 1, 2019, 00:00

  • PGI32 EVALUATION OF THE COST-UTILITY OF THE YORK FAECAL CALPROTECTIN CARE PATHWAY

    Nov 1, 2019, 00:00

  • PNS33 PUBLICATION TREND AND CITATION ANALYSIS OF ARTICLES PUBLISHED IN "VALUE IN HEALTH” BETWEEN 1998-2019

    Nov 1, 2019, 00:00

  • PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN.

    Nov 1, 2019, 00:00

  • PCN281 IDENTIFYING THE KEY CHALLENGES IN EVALUATION AND PRICING OF ONCOLOGY COMBINATION THERAPIES AND FUTURE POLICY CHANGES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PMD14 COST-EFFECTIVENESS ANALYSIS OF THE USE OF MICROINVASIVE SURGERY WITH ISTENT® IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS IN THE MEXICAN PUBLIC HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • PBI93 CHANGE IN PERSISTENCE OVER TIME OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL OBSERVATIONAL LONGITUDINAL POPULATION STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

    Nov 1, 2019, 00:00

  • PCV105 A SCOPING REVIEW OF INTERNATIONAL MODELS OF ADULT SPECIALIST CARDIAC NETWORKS

    Nov 1, 2019, 00:00

  • PND79 HOW DIFFERENT ARE MIGRAINE PATIENTS TREATED BY GENERAL PRACTITIONERS VERSUS THOSE TREATED BY NEUROLOGISTS?

    Nov 1, 2019, 00:00

  • Cancer - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMD13 COST-UTILITY ANALYSIS OF ISTENT INJECT IN MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA IN JAPAN

    Nov 1, 2019, 00:00

  • PND11 IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROTOCOL ON MULTIPLE SCLEROSIS PATIENTS' ADHERENCE TO THEIR ORAL TREATMENT WITH DIMETHYL FUMARATE: TECPHIE, A RANDOMIZED STUDY VS USUAL PRACTICE (INTERIM RESULTS)

    Nov 1, 2019, 00:00

  • PCN516 EXPLORING THE CURRENT STATUS OF NEUROENDOCRINE TUMOURS: A POPULATION-BASED ANALYSIS OF EPIDEMIOLOGY, MANAGEMENT AND USE OF RESOURCES

    Nov 1, 2019, 00:00

  • PUK22 A RETROSPECTIVE COHORT STUDY ON CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND DISEASE OUTCOMES IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES USING A JAPANESE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PCN328 CHANGING EPIDEMIOLOGY AND TREATMENT ALGORITHM IN PANCREATIC CANCER IN GERMANY 2017-2018

    Nov 1, 2019, 00:00
  • «
  • 51
  • 52 (current)
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »